tiprankstipranks
Advertisement
Advertisement

RNXT Stock Latest News

RenovoRx announces FDA Orphan Drug Designation for oxaliplatin
The FlyRenovoRx announces FDA Orphan Drug Designation for oxaliplatin
24d ago
RNXT
RenovoRx announces pharmacokinetic data using TAMP platform
PremiumThe Fly
RenovoRx announces pharmacokinetic data using TAMP platform
26d ago
RNXT
RenovoRx Earnings Call Signals Commercial Inflection
PremiumCompany Announcements
RenovoRx Earnings Call Signals Commercial Inflection
1M ago
RNXT
RenovoRx reports Q1 adjusted EPS (8c), consensus (8c)
PremiumThe Fly
RenovoRx reports Q1 adjusted EPS (8c), consensus (8c)
1M ago
RNXT
RenovoRx sees FY26 revenue $3M-$4M, consensus $3.24M
PremiumThe Fly
RenovoRx sees FY26 revenue $3M-$4M, consensus $3.24M
1M ago
RNXT
RenovoRx files to sell 8.44M shares of common stock for holders
PremiumThe FlyRenovoRx files to sell 8.44M shares of common stock for holders
2M ago
RNXT
RenovoRx: Building Commercial Momentum Ahead of TIGeR-PaC Readout Supports Buy-Rated Risk‑Reward Profile
Premium
Ratings
RenovoRx: Building Commercial Momentum Ahead of TIGeR-PaC Readout Supports Buy-Rated Risk‑Reward Profile
2M ago
RNXT
RenovoRx secures Japanese patent allowance for targeted drug-delivery
Premium
The Fly
RenovoRx secures Japanese patent allowance for targeted drug-delivery
2M ago
RNXT
RenovoRx Reports 2025 Results and Advances TIGeR-PaC Trial
PremiumCompany Announcements
RenovoRx Reports 2025 Results and Advances TIGeR-PaC Trial
3M ago
8K
RNXT
RNXT Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
RNXT Upcoming Earnings Report: What to Expect?
3M ago
RNXT
RenovoRx’s TIGeR-PaC Phase III trial surpasses 100 randomized patients
PremiumThe Fly
RenovoRx’s TIGeR-PaC Phase III trial surpasses 100 randomized patients
3M ago
RNXT
RenovoRx Raises $10 Million in Oversubscribed Private Placement
PremiumCompany Announcements
RenovoRx Raises $10 Million in Oversubscribed Private Placement
3M ago
8K
RNXT
RenovoRx prices 10.6M shares at 93.8c in private placement
PremiumThe FlyRenovoRx prices 10.6M shares at 93.8c in private placement
3M ago
RNXT
RenovoRx advances RenovoCath adoption at U.S. cancer centers
Premium
The Fly
RenovoRx advances RenovoCath adoption at U.S. cancer centers
4M ago
RNXT
RenovoRx announces acceptance of clinical data abstract at 2026 SIR
Premium
The Fly
RenovoRx announces acceptance of clinical data abstract at 2026 SIR
4M ago
RNXT
RenovoRx establishes RenovoCath Medical Advisory Board
PremiumThe Fly
RenovoRx establishes RenovoCath Medical Advisory Board
4M ago
RNXT
RenovoRx Appoints Veteran Executive Mark Voll as CFO
PremiumCompany Announcements
RenovoRx Appoints Veteran Executive Mark Voll as CFO
4M ago
8K
RNXT
RenovoRx appoints Voll as Chief Financial Officer
PremiumThe Fly
RenovoRx appoints Voll as Chief Financial Officer
5M ago
RNXT
RenovoRx announces new clinical data on TAMP therapy platform
PremiumThe Fly
RenovoRx announces new clinical data on TAMP therapy platform
5M ago
RNXT
RenovoRx initiated with a Buy at JonesResearch
PremiumThe FlyRenovoRx initiated with a Buy at JonesResearch
5M ago
RNXT
RenovoRx expands RenovoCath commercial adoption to nine cancer centers
Premium
The Fly
RenovoRx expands RenovoCath commercial adoption to nine cancer centers
5M ago
RNXT
RenovoRx to announce new clinical data from Phase III TIGeR-PaC trial
Premium
The Fly
RenovoRx to announce new clinical data from Phase III TIGeR-PaC trial
5M ago
RNXT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >